Suppr超能文献

小分子靶向增殖细胞核抗原染色质结合抑制肿瘤细胞生长。

Small-molecule targeting of proliferating cell nuclear antigen chromatin association inhibits tumor cell growth.

机构信息

Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA.

出版信息

Mol Pharmacol. 2012 Jun;81(6):811-9. doi: 10.1124/mol.112.077735. Epub 2012 Mar 7.

Abstract

Proliferating cell nuclear antigen (PCNA), a potential anticancer target, forms a homotrimer and is required for DNA replication and numerous other cellular processes. The purpose of this study was to identify novel small molecules that modulate PCNA activity to affect tumor cell proliferation. An in silico screen of a compound library against a crystal structure of PCNA and a subsequent structural similarity search of the ZINC chemical database were carried out to derive relevant docking partners. Nine compounds, termed PCNA inhibitors (PCNA-Is), were selected for further characterization. PCNA-I1 selectively bound to PCNA trimers with a dissociation constant (K(d)) of ~0.2 to 0.4 μM. PCNA-Is promoted the formation of SDS-refractory PCNA trimers. PCNA-I1 dose- and time-dependently reduced the chromatin-associated PCNA in cells. Consistent with its effects on PCNA trimer stabilization, PCNA-I1 inhibited the growth of tumor cells of various tissue types with an IC(50) of ~0.2 μM, whereas it affected the growth of nontransformed cells at significantly higher concentrations (IC(50), ~1.6 μM). Moreover, uptake of BrdU was dose-dependently reduced in cells treated with PCNA-I1. Mechanistically the PCNA-Is mimicked the effect of PCNA knockdown by siRNA, inducing cancer cell arrest at both the S and G(2)/M phases. Thus, we have identified a class of compounds that can directly bind to PCNA, stabilize PCNA trimers, reduce PCNA association with chromatin, and inhibit tumor cell growth by inducing a cell cycle arrest. They are valuable tools in studying PCNA function and may be useful for future PCNA-targeted cancer therapy.

摘要

增殖细胞核抗原(PCNA)是一种潜在的抗癌靶点,它形成三聚体,是 DNA 复制和许多其他细胞过程所必需的。本研究的目的是鉴定能调节 PCNA 活性以影响肿瘤细胞增殖的新型小分子。对 PCNA 晶体结构进行计算机筛选和随后对 ZINC 化学数据库进行结构相似性搜索,以获得相关的对接伙伴。选择了 9 种化合物,称为 PCNA 抑制剂(PCNA-Is)进行进一步表征。PCNA-I1 选择性地与 PCNA 三聚体结合,解离常数(Kd)约为 0.2 到 0.4 μM。PCNA-Is 促进 SDS 抗性 PCNA 三聚体的形成。PCNA-I1 剂量和时间依赖性地降低细胞中染色质相关的 PCNA。与稳定 PCNA 三聚体的作用一致,PCNA-I1 以约 0.2 μM 的 IC50 抑制各种组织类型的肿瘤细胞生长,而在显著更高的浓度(IC50,约 1.6 μM)影响非转化细胞的生长。此外,用 PCNA-I1 处理的细胞中 BrdU 的摄取呈剂量依赖性降低。从机制上讲,PCNA-Is 模拟了 PCNA 敲低的效果,通过 siRNA 诱导癌细胞在 S 和 G2/M 期停滞。因此,我们已经鉴定出一类能够直接与 PCNA 结合、稳定 PCNA 三聚体、减少 PCNA 与染色质的结合并通过诱导细胞周期停滞来抑制肿瘤细胞生长的化合物。它们是研究 PCNA 功能的有价值的工具,并且可能对未来基于 PCNA 的癌症治疗有用。

相似文献

1
Small-molecule targeting of proliferating cell nuclear antigen chromatin association inhibits tumor cell growth.
Mol Pharmacol. 2012 Jun;81(6):811-9. doi: 10.1124/mol.112.077735. Epub 2012 Mar 7.
2
Antitumor effects of a novel small molecule targeting PCNA chromatin association in prostate cancer.
Mol Cancer Ther. 2014 Dec;13(12):2817-26. doi: 10.1158/1535-7163.MCT-14-0522. Epub 2014 Sep 24.
3
Target validation and structure-activity analysis of a series of novel PCNA inhibitors.
Pharmacol Res Perspect. 2015 Mar;3(2):e00115. doi: 10.1002/prp2.115.
5
Proliferating cell nuclear antigen inhibitors block distinct stages of herpes simplex virus infection.
PLoS Pathog. 2023 Jul 24;19(7):e1011539. doi: 10.1371/journal.ppat.1011539. eCollection 2023 Jul.
7
Targeting Proliferating Cell Nuclear Antigen (PCNA) as an Effective Strategy to Inhibit Tumor Cell Proliferation.
Curr Cancer Drug Targets. 2020;20(4):240-252. doi: 10.2174/1568009620666200115162814.
8
Proliferating cell nuclear antigen (PCNA) may function as a double homotrimer complex in the mammalian cell.
J Biol Chem. 2005 Apr 8;280(14):13888-94. doi: 10.1074/jbc.M500304200. Epub 2005 Feb 1.
10
The Anticancer Activity of a First-in-class Small-molecule Targeting PCNA.
Clin Cancer Res. 2018 Dec 1;24(23):6053-6065. doi: 10.1158/1078-0432.CCR-18-0592. Epub 2018 Jul 2.

引用本文的文献

3
4
Proliferating Cell Nuclear Antigen in the Era of Oncolytic Virotherapy.
Viruses. 2024 Aug 7;16(8):1264. doi: 10.3390/v16081264.
5
Identification of a potent PCNA-p15-interaction inhibitor by autodisplay-based peptide library screening.
Microb Biotechnol. 2024 Apr;17(4):e14471. doi: 10.1111/1751-7915.14471.
6
The potential of PCNA inhibition as a therapeutic strategy in cervical cancer.
J Med Virol. 2023 Nov;95(11):e29244. doi: 10.1002/jmv.29244.
7
Therapeutic Targeting of DNA Replication Stress in Cancer.
Genes (Basel). 2023 Jun 26;14(7):1346. doi: 10.3390/genes14071346.
8
Proliferating cell nuclear antigen inhibitors block distinct stages of herpes simplex virus infection.
PLoS Pathog. 2023 Jul 24;19(7):e1011539. doi: 10.1371/journal.ppat.1011539. eCollection 2023 Jul.
9
RNA polymerase II associates with active genes during DNA replication.
Nature. 2023 Aug;620(7973):426-433. doi: 10.1038/s41586-023-06341-9. Epub 2023 Jul 19.
10
Molecular Glue Discovery: Current and Future Approaches.
J Med Chem. 2023 Jul 27;66(14):9278-9296. doi: 10.1021/acs.jmedchem.3c00449. Epub 2023 Jul 12.

本文引用的文献

1
Potent kinetic stabilizers that prevent transthyretin-mediated cardiomyocyte proteotoxicity.
Sci Transl Med. 2011 Aug 24;3(97):97ra81. doi: 10.1126/scitranslmed.3002473.
2
Molecular interaction studies using microscale thermophoresis.
Assay Drug Dev Technol. 2011 Aug;9(4):342-53. doi: 10.1089/adt.2011.0380.
3
Membrane transport and intracellular sequestration of novel thiosemicarbazone chelators for the treatment of cancer.
Mol Pharmacol. 2010 Oct;78(4):675-84. doi: 10.1124/mol.110.066126. Epub 2010 Jul 6.
4
MolProbity: all-atom structure validation for macromolecular crystallography.
Acta Crystallogr D Biol Crystallogr. 2010 Jan;66(Pt 1):12-21. doi: 10.1107/S0907444909042073. Epub 2009 Dec 21.
5
Repair activities of human 8-oxoguanine DNA glycosylase are stimulated by the interaction with human checkpoint sensor Rad9-Rad1-Hus1 complex.
DNA Repair (Amst). 2009 Oct 2;8(10):1190-200. doi: 10.1016/j.dnarep.2009.06.004. Epub 2009 Jul 16.
6
Structure and functional implications of the human rad9-hus1-rad1 cell cycle checkpoint complex.
J Biol Chem. 2009 Jul 31;284(31):20457-61. doi: 10.1074/jbc.C109.022384. Epub 2009 Jun 17.
7
The iron chelator Dp44mT does not protect myocytes against doxorubicin.
J Inorg Biochem. 2009 Jul;103(7):1093-101. doi: 10.1016/j.jinorgbio.2009.05.007. Epub 2009 May 21.
8
The DNA binding domain of human DNA ligase I interacts with both nicked DNA and the DNA sliding clamps, PCNA and hRad9-hRad1-hHus1.
DNA Repair (Amst). 2009 Aug 6;8(8):912-9. doi: 10.1016/j.dnarep.2009.05.002. Epub 2009 Jun 11.
9
PCNA on the crossroad of cancer.
Biochem Soc Trans. 2009 Jun;37(Pt 3):605-13. doi: 10.1042/BST0370605.
10
The iron chelator Dp44mT causes DNA damage and selective inhibition of topoisomerase IIalpha in breast cancer cells.
Cancer Res. 2009 Feb 1;69(3):948-57. doi: 10.1158/0008-5472.CAN-08-1437. Epub 2009 Jan 27.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验